Cancer Immunotherapy: Volume 209 | Agenda Bookshop Skip to content
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B13=David B. Teplow
Category1=Non-Fiction
Category=PSB
Category=PSD
COP=United States
Delivery_Pre-order
Language_English
PA=Not yet available
Price_€100 and above
PS=Forthcoming
softlaunch

Cancer Immunotherapy: Volume 209

★★★★★
★★★★★

English

Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma. Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment. See more
€126.34
€132.99
Save 5%
Age Group_Uncategorizedautomatic-updateB13=David B. TeplowCategory1=Non-FictionCategory=PSBCategory=PSDCOP=United StatesDelivery_Pre-orderLanguage_EnglishPA=Not yet availablePrice_€100 and abovePS=Forthcomingsoftlaunch

Will deliver when available. Publication date 01 Nov 2024

Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 01 Nov 2024
  • Publisher: Elsevier Science Publishing Co Inc
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780443235344

About

David B. Teplow Ph.D. is a Professor of Neurology Emeritus at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides such as the amyloid ß-protein (Alzheimer's disease) and a-synuclein (Parkinsons disease) form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA Dr. Teplow was a faculty member in the Department of Neurology Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles books and book chapters and commentaries in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept